• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    11/5/24 4:15:28 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TERN alert in real time by email
    SC 13G/A 1 TERN_SC13GA1.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    (AMENDMENT NO. 1)

    TERNS PHARMACEUTICALS, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.0001 PER SHARE
    (Title of Class of Securities)

    880881107
    (CUSIP Number)

    SEPTEMBER 30, 2024
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    880881107

    SCHEDULE 13G

    Page  
    2
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Core Strategies (US) LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,514,446
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,514,446
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,514,446
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     1.8%
    12 TYPE OF REPORTING PERSON

     OO


                         
    CUSIP No.
     
    880881107

    SCHEDULE 13G

    Page  
    3
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,628,534
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,628,534
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,628,534
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     1.9%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    880881107

    SCHEDULE 13G

    Page  
    4
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,628,534
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,628,534
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,628,534
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     1.9%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    880881107

    SCHEDULE 13G

    Page  
    5
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,628,534
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,628,534
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,628,534
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     1.9%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    880881107

     SCHEDULE 13G

    Page  
    6
      of   
    11
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      Terns Pharmaceuticals, Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    1065 East Hillsdale Boulevard, Suite 100
    Foster City, California 94404

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Integrated Core Strategies (US) LLC
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.0001 per share ("Common Stock")
     
      (e) CUSIP Number:
    880881107
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    880881107

     SCHEDULE 13G

    Page  
    7
      of   
    11
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    880881107

     SCHEDULE 13G

    Page  
    8
      of   
    11

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ .

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    880881107

    SCHEDULE 13G

    Page  
    9
      of   
    11

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of November 4, 2024, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    880881107

    SCHEDULE 13G

    Page  
    10
      of   
    11
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: November 4, 2024

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    880881107

    SCHEDULE 13G

    Page  
    11
      of   
    11
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.0001 per share, of Terns Pharmaceuticals, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: November 4, 2024

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $TERN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TERN

    DatePrice TargetRatingAnalyst
    11/4/2025$20.00Neutral → Buy
    H.C. Wainwright
    11/3/2025Mkt Perform → Outperform
    William Blair
    10/15/2025$20.00Buy
    Truist
    9/17/2025$15.00Overweight
    Barclays
    9/4/2025Neutral
    H.C. Wainwright
    2/28/2025Mkt Perform
    William Blair
    10/31/2024$82.00Outperform
    Oppenheimer
    6/22/2023$16.00Buy
    Mizuho
    More analyst ratings

    $TERN
    SEC Filings

    View All

    SEC Form 8-K filed by Terns Pharmaceuticals Inc.

    8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    12/11/25 7:45:19 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Terns Pharmaceuticals Inc.

    424B5 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    12/11/25 7:44:01 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Terns Pharmaceuticals Inc.

    424B5 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

    12/9/25 7:46:21 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are $747.5 million. All of the securities were off

    12/11/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Announces Pricing of Upsized $650 Million Public Offering

    FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters' option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an add

    12/9/25 11:30:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Announces Proposed Public Offering

    FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Terns expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares and pre-funded warrants to be sold in th

    12/9/25 6:12:55 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Terns Pharmaceuticals upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Terns Pharmaceuticals from Neutral to Buy and set a new price target of $20.00

    11/4/25 8:12:25 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals upgraded by William Blair

    William Blair upgraded Terns Pharmaceuticals from Mkt Perform to Outperform

    11/3/25 10:27:19 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Terns Pharmaceuticals with a new price target

    Truist initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $20.00

    10/15/25 8:33:02 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gengos Andrew bought $39,283 worth of shares (10,000 units at $3.93), increasing direct ownership by 67% to 25,000 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/30/25 5:38:10 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Burroughs Amy L. bought $90,230 worth of shares (23,314 units at $3.87), increasing direct ownership by 98% to 47,083 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/25/25 6:08:58 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Gengos Andrew bought $57,082 worth of shares (15,000 units at $3.81) (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/16/25 6:05:21 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Quigley Jill M. exercised 24,520 shares at a strike of $9.24 and sold $441,360 worth of shares (24,520 units at $18.00) (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    11/5/25 6:17:46 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Kuriakose Emil sold $7,407 worth of shares (944 units at $7.85), decreasing direct ownership by 2% to 51,520 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    10/2/25 7:24:36 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Kuriakose Emil sold $3,640 worth of shares (853 units at $4.27), decreasing direct ownership by 2% to 52,464 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    7/3/25 2:55:49 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Leadership Updates

    Live Leadership Updates

    View All

    Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

    FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. "We are delighted to have Andrew join the Terns' team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew's contributions as we continue to advance our mission to transfor

    2/24/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

    FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's Board of Directors, effective immediately. In conjunction with Mr. Azelby's appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service. "I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operationa

    2/20/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

    FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide

    11/18/24 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 7:00:26 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/14/24 5:51:38 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TERN
    Financials

    Live finance-specific insights

    View All

    Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

    64% MMR achievement by 24 weeks across all efficacy evaluable patients  75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today a

    12/8/25 2:45:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract  Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates. "We're thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1

    11/10/25 4:05:00 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

    Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (NASDAQ:TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in participants with previously treated chronic myeloid leukemia (CML) has been selected for oral presentation on December 8, 2025 at the 67th American Society of Hema

    11/3/25 9:05:00 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care